Why Santen ends Neurim-style SPCs

The July 9 Santen decision ( C-673/18) from the Court of Justice of the European Union (CJEU) resolves the issues that arose from the earlier Neurim decision ( C-130/11) issued by the same court. Essentially, and unusually, the CJEU reversed its own earlier decision.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

22 October 2026 Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.

Pharma

Amarin and Hikma call time on six-year skinny label fight

22 October 2026 Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.

Pharma

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

20 October 2026 In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.

More features

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

Amarin and Hikma call time on six-year skinny label fight

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

Boehringer and Dr Reddy’s spar over plausibility as trial wraps up

Haynes Boone expands in California with new office

Accord’s generic hopes dashed in cyanide antidote ruling

Novo’s semaglutide protection weakens after European ruling

Brazilian firm appoints patent strategist to lead department

Why Santen ends Neurim-style SPCs

More on this story

Editor's picks

Editor's picks

More features